Around the World in 120 Days: The World is Small: Understanding Biotech Business in the Global Framework
Thursday, March 20 2014
8:00 am – 10:00 am
Location: MassBio, 300 Technology Square, 8th Floor, Cambridge, MA
Join us for Part I of Forum series:
Around the World in 120 Days: Biotech on a Global Scale
Massachusetts has one of the most successful bioclusters in the world and we are the envy of many. However, the current landscape for biotech and pharma companies has probably never been more challenging. In order to succeed, you can no longer just focus on your backyard or the traditional developed markets. Tomorrow’s successful biopharma companies need to start planning their international business strategy today.
This Forum will help you understand key components of an effective strategy such as:
• How to access foreign markets
• What opportunities and pitfalls exist
• How the cultural and business landscape changes the way you do business globally
Please join us for an insightful look at the current and expected global biopharma landscape, hear from seasoned veterans who have successfully launched and led global expansion initiatives and learn why you need to start thinking about your global strategy today.
- Pedro Arboleda, Director, Strategy, Monitor Deloitte
- Dane Bedward, Senior Life Science Executive, former Senior V.P. International Strategic Development and GM Eurasia, Genzyme
- Judy Hackett, Global Payer Evidence Director, AstraZeneca
- Markus Warmuth, President and Chief Executive Officer, H3 Biomedicine
- Peter Abair, Director, Economic Development & Global Affairs, MassBio
- Angelos Dovletoglou, Executive Director, Preclinical Development Sciences, Epizyme
This Forum is presented by the Entrepreneur's University, Formulation & Drug Deliery, and Drug Discovery Forum Working Groups.
Pedro Arboleda, Director, Strategy, Monitor Deloitte
Pedro Arboleda is a Director at Monitor Deloitte successfully leading life sciences and health care-related commercial strategy projects since 2001 for leading pharmaceutical, biotechnology, medical devices, and health care payer companies as they seek new customers and markets in North America, Europe and emerging economies, such as Mexico, Brazil, and China.
Pedro is currently focused on advising clients on strategic options related to engaging national governments as changes in national health care systems in US and emerging economies take hold, creating complex corporate / marketing strategy and license-to-operate issues. Work has included critical commercial strategy, advocacy, outreach, and stakeholder engagement advisory support. Pedro’s work has been cited in The Economist magazine’s 2007 and 2009 Special Reports.
Examples of recent projects include:
Advised a $31bil pharma multinational on public-private partnership strategy and investment options in relevant emerging economies, leading to greater rationalization of investment options
Advised $4bil global biotech on China entry strategy and Key Opinion Leader engagement in China that led to opening of Shanghai office Advised drug-device combination brand launch team of a $7bil medical device manufacturer on go-to-market strategy. Brand launch is widely considered one of the largest and most successful product launches in industry history
Led a technology center location project that directly impacted R&D investments of $200million for three research centers in India, Brazil, and China for the CTO of a Fortune 100 $11bil client
Advised life science senior executives in Spain and the US on various innovation issues related to the transformation of their health care sector, including developing approaches to increasing Chinese foreign-direct investments
Managed initiatives for the Chinese Academy of Sciences and the US-Russia Business Council, recommending policies to advance biopharma-related activities via collaborative R&D networks
Pedro received an MBA from Cornell University in 1997, a Masters in Latin American Studies from Stanford University in 1995, and a Bachelors of Science in International Relations from Georgetown University in 1991
Dane Bedward, former Senior V.P. International Strategic Development and GM Eurasia, Genzyme International
Dane is a senior executive with extensive experience in biotech and medical devices with a focus on sales, marketing, government relations and general management in both international and domestic markets. Dane has a consistent history of successful new product launches, increasing revenue and ensuring profitability targets. He is presently the CEO of NeuroBot Inc a commercialization advisory firm specialized in life sciences companies. Dane spent over 16 years at Genzyme Corporation in a variety of senior international executive roles in both opening and leading new international operations. This included international market development in all ex-US regions: Europe, Asia, Eurasia, Latin America and North America. He restructured Latin American and Canadian subsidiaries, as well as the International Biosurgery Business Unit, resulting in a significant growth and profitability improvement, integrated 21 countries in Eurasia to the European group of Genzyme and coordinated the development of strategic plans for the International Group.
Dane started his career in management at Johnson & Johnson Company in a variety of product and marketing roles in Canada and Europe.
Dane is a graduate of the University of Ottawa with a BS in Biology. He has been a member of numerous corporate, not for profit and association boards of directors.
Angelos Dovletoglou, Executive Director of Preclinical Development Sciences, Epizyme
Angelos Dovletoglou, Ph.D. has served as the head of preclinical development at Epizyme since 2011. Epizyme is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative personalized therapeutics for patients with genetically defined cancers. Prior to joining Epizyme was responsible for all small molecules CMC teams supporting neurology, immunology and oncology programs from discovery to commercial launch at Biogen Idec and coordinated the CMC development and manufacturing plans for the oral MS drug Tecfidera (BG-12). Prior to that, at Merck Research Labs and Momenta Pharma Dr. Dovletoglou managed early- and late-stage CMC development activities, and developed and implemented CMC strategies in support of global filings. Over the last 20 years has contributed to six NDA/WMA filings and commercial manufacturing launches and multiple FDA pre-approval inspections. He has been a member of the SAB at Cocoon Biotech since 2013 developing novel OA therapies. Dr. Dovletoglou earned his Ph.D. in Inorganic Chemistry from the University of North Carolina at Chapel Hill and B.S. in Chemistry from the University of Athens, Greece.
Judy Hackett, Global Payer Evidence Director, AstraZeneca
Judy Hackett received her Pharmacy Degree from the University of Toronto. She subsequently completed her M.B.A. at York University. As well she has a graduate degree in Evaluation and Outcomes from the Faculty of Medicine, University of Toronto. She began her career working in community pharmacy and then went onto work as a payer where she developed and managed drug formularies as well as evaluated DUR reports. She has worked for the past fourteen years in the pharmaceutical industry in the government affairs, health economics and pricing.
Markus Warmuth, M.D., President and Chief Executive Officer, H3 Biomedicine
Dr. Markus Warmuth joined H3 Biomedicine as Chief Scientific Officer in August 2011 and became President and Chief Executive Officer on October 1, 2011. Markus brings significant experience in cancer biology, drug discovery and clinical oncology to H3. During his career as a pharmaceutical industry research executive, he has successfully built and shaped oncology research groups and portfolios.
Prior to joining H3, Markus was Head of Oncology Drug Discovery for the Novartis Institute for Biomedical Research (NIBR), Cambridge (U.S.) Site. There, he oversaw a significant part of NIBR’s global oncology drug discovery portfolio from target discovery to clinical development.
Markus studied and received his doctorate in medicine from the Ludwig-Maximilians-University of Munich, Germany. He trained in Internal medicine and oncology at the University of Munich. From 1998 to 2002, he had an appointment as a principal scientist with the “Clinical Cooperation Group Signaling” at the German National Research Center of Environment and Health (GSF), where he studied the mechanism of action of and resistance to multiple small molecule kinase inhibitors in leukemia and lymphoma.
From 2002 to April 2008, Markus worked at the Genomics Institute of the Novartis Research Foundation (GNF), San Diego, where he was Director of Kinase Biology, Head of the Oncology Pharmacology Program and a member of GNF’s Research and Drug Discovery Steering Committee.